Lifecode Health specializes in providing patient-specific molecular information for cancer care, leveraging advanced technologies in clinical genomics and next-generation sequencing (NGS). Their approach focuses on translating complex genomic data into actionable insights that are concise and accurate, addressing the challenges posed by the vast amounts of information generated through NGS. Lifecode's commitment to improving patient outcomes is supported by a team of experts in various fields, including data science, computational biology, and machine learning, who work collaboratively to enhance the interpretation of genomic data.

As a CAP accredited and CLIA certified clinical laboratory, Lifecode combines the capabilities of a software company with the rigor of a world-class clinical lab. Their flagship product, the Lifecode Pan Cancer Somatic Panel, exemplifies their dedication to personalized cancer care, offering targeted molecular tumor profiling to healthcare providers. With backing from notable investors like Sequoia Capital and The Mayo Clinic, Lifecode is positioned at the forefront of cancer genomics, striving to make molecular profiling more accessible and clinically relevant for patients and healthcare professionals alike.

United States

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable.   The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

Lifecode

Company Details